TITLE:
Envita’s Precision Cancer Care: 35-Fold Improvement in Response Rates
AUTHORS:
Sheba Goklany, John C. Oertle III, Ronald Matthias Jr., Daniel Warren, David Medina, Rory Sears, Robert Zieve, Kendra Quart, Christopher Aussems, Jon Moma, Shannon Miller, Zach Poteet, Conner Coffin, Courtney Middleton, Erika Ware, Phylicia Zarnosky, Julie Nowak, Winlove Suasin, Daniel Conway, Chad Burk, Ruth Tan-Lim, Dino Prato
KEYWORDS:
Envita Medical Centers, Late-stage Cancer, Overall Response Rate, Quality of Life, Circulating Tumor Cells (CTCs), Mutant Allele Frequency (MAF), Precision Care
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.15 No.4,
April
17,
2024
ABSTRACT: New clinical approaches are imperative beyond the widely adopted National Comprehensive Cancer Network (NCCN) guidelines, utilized by prominent cancer institutions. Cancer is the leading cause of death among individuals younger than 85 years within the United States. Despite significant technological advances, including the expenditure of hundreds of billions, treatment outcomes and overall survival have not notably improved for most types of advanced cancer over the last several decades. Over the past 24 years, Envita Medical Centers has pioneered a unique form of personalized treatment approach for late-stage and refractory cancer patients, introducing groundbreaking innovations in the field. Our integrated algorithm utilizes advanced genomics, transcriptomics, and highly tailored immunotherapy, resulting in remarkable outcome improvements. This study presents Envita’s innovative personalized treatment algorithms and examines the response outcomes of 199 late-stage cancer patients treated at Envita Medical Centers over a two-year period. Compared to standard of care and palliative chemotherapy, Envita’s treatment demonstrated a remarkable 35-fold improvement in overall response rates (Figure 1). Moreover, 88% of the patients, the majority presenting with Stage 3 or 4 cancer, experienced a 43-fold improvement in quality of life with minimal side effects, as compared to standard of care chemotherapy and palliative care. This revolutionary success is attributed to Envita’s personalized therapeutic algorithms, which incorporate customized immunotherapy. Envita’s precision care approach has also achieved a 100% better response rate compared to over 65 global chemotherapy clinical trials with more than 2700 patients. The results from this study suggest that a wider utilization of Envita’s personalized approach can significantly benefit patients with late-stage and refractory cancer.